Arroyo-Mayorga G, Arroyo-Del Castillo JG, Zazueta-López IB

Language: Spanish
References: 15
Page: 303-308
PDF size: 291.04 Kb.

ABSTRACT

Astrocytomas or brain gliomas are the most common type of intraaxial tumors. In Mexico they account for 2.3% of primary central nervous system neoplasms. During the management of these tumors it is frequently a need to determine which cases are candidates to radiotherapy, chemotherapy or both. Genetic markers for the vast majority of tumors exist, some are useful to guide their treatment. Description of the available markers that help reach and guide the treatment these patients is made. DNA methylation promoter in a CpG island methylator phenotype was found in glioblastomas. Magnetic resonance spectroscopic imaging with hyperpolarized pyruvate highlight the difference between tumor’s persistence and radiotherapy effects, as well as the immediate response to temozolamide. The use of these techniques is proposed to optimize the therapy for these patients.

REFERENCES

1. Greenberg M. Stroke. En: Greenberg M Handbook of Neurosurgery. 7a ed. USA. Thieme Publishers; 2013. p.1010-1032.

2. Ferguson SD, Xiu J, Weathers SP, Zhou S, Kesari S, Weiss SE et al. GBM-associated mutations and altered protein expression are more common in young patients. Oncotarget. 2016;7(43):69466-69478.

3. Millward CP, Brodbelt AR, Haylock B, Zakaria R, Baborie A, Crooks D et al. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy. Acta Neurochir (Wien). 2016;158(10):1943-53.

4. Chaumeil MM, Radoul M, Najac C, Eriksson P, Viswanath P, Blough M et al. Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring. Neuroimage Clin. 2016; 23(12):180-189.

5. Chaurasia A, Park SH, Seo JW, Park CK. Immunohistochemical analysis of ATRX, IDH1 and p53 in glioblastoma and their correlations with patient survival. J Korean Med Sci. 2016; 31(8): 1208-1214.

6. Roszkowski K, Furtak J, Zurawski B, Szylberg T and Lewandowska MA. Potential role of methylation marker in glioma supporting clinical decisions. Int. J. Mol. Sci. 2016; 17 (11): 1876-1881.

7. Rodriguez FJ, Vizcaino MA, Lin MT. Recent advances on the molecular pathology of glial neoplasms in children and adults. J Mol Diagn. 2016; 18 (5):620-634.

8. Mandel JJ, Caccia D, Liu D, Wilson C, Aldape K, Fuller G, de Groot JF. Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma. J Neuroncol. 2016;129(1): 147-154.

9. Ohno M, Narita Y, Miyakita Y, Matsushita Y, Arita H, Yonesawa M et al. Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome. Jpn J Clin Oncol. 2016; 46(1):31-39.

10. von Felten LS, Frank S, Boulay JL, Mariani L . IDH mutation is associated with higher risk of malignant transformation in low-grade glioma. J Neurooncol. 2016; 127(2):363-372.

11. Xiu J, Piccioni D, Juarez T, Pingle SC, Hu J, Rudnick J et.al. Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies. Oncotarget. 2016; 7(16): 21556–21569.

12. Hailong L, Jiye L, Gang Ch, Jianning Z, Xuezhen L. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy. Clin Neurol Neurosurg. 2016;151 (1): 31-36.

13. Kim HR, Lee JJ, Lee JI, Nam DH, Suh YL, Seol HJ. Malignant glioma with neuronal marker expression: A clinicopathological study of 18 cases. J Korean Neurosurg Soc. 2016; 59(1): 44–51.

14. Wang HY, Tang K, Liang TY, Zhang WZ, Li JY, Wang W et al. The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas. J Exp Clin Cancer Res. 2016;35(86):1-9.

15. Reich TR, Switzeny OJ, Renovanz M, Sommer C, Kaina B, Christmann M et al. Epigenetic silencing of XAF1 in highgrade gliomas is associated with IDH1 status and improved clinical outcome. Oncotarget 2017; 8 (1): 15071-15084.